Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

被引：0
|
作者：
Elza Muscelli
Brenno Astiarraga
Elisabetta Barsotti
Andrea Mari
Freimut Schliess
Leszek Nosek
Tim Heise
Uli C. Broedl
Hans-Juergen Woerle
Ele Ferrannini
机构：
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] C.N.R. Institute of Neuroscience,undefined
[3] Profil,undefined
[4] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[5] CNR Institute of Clinical Physiology,undefined
来源：
Diabetologia | 2016年 / 59卷
关键词：
Empagliflozin; Endogenous glucose production; Glycosuria; Metformin; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：700 / 708
页数：8
相关论文
共 50 条
  • [41] Metabolic modelling of the human gut microbiome in type 2 diabetes patients in response to metformin treatment
    Ezzamouri, Bouchra
    Rosario, Dorines
    Bidkhori, Gholamreza
    Lee, Sunjae
    Uhlen, Mathias
    Shoaie, Saeed
    NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2023, 9 (01)
  • [42] Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes
    List, James F.
    Woo, Vincent C.
    Villegas, Enrique Morales
    Tang, Weihua
    Fiedorek, Fred T.
    DIABETES, 2008, 57 : A94 - A94
  • [43] Higher concentration of 25-hydroxycholesterol in treatment-naive patients with type 2 diabetes compared to healthy individuals
    Kai, Takahito
    Hirayama, Satoshi
    Soda, Satoshi
    Fuwa, Fumiko
    Nakagawa, Saori
    Ueno, Tsuyoshi
    Hori, Atsushi
    Miida, Takashi
    JOURNAL OF CLINICAL LIPIDOLOGY, 2023, 17 (03) : 384 - 391
  • [44] Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes
    List, J. F.
    Woo, V.
    Morales, E.
    Tang, W.
    Fiedorek, F. T.
    DIABETOLOGIA, 2008, 51 : S22 - S23
  • [45] Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : 1773 - 1788
  • [46] Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
    Lingvay, Ildiko
    Beetz, Nadine
    Sennewald, Regina
    Schuler-Metz, Annette
    Bertulis, Julia
    Loley, Christina
    Lang, Benjamin
    Lippert, Caroline
    Lee, Jisoo
    Manning, Linda Shapiro
    Terada, Derek
    POSTGRADUATE MEDICINE, 2020, 132 (04) : 337 - 345
  • [47] Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
    Rodbard, Helena W.
    Rosenstock, Julio
    Canani, Luis H.
    Deerochanawong, Chaicharn
    Gumprecht, Janusz
    Lindberg, Soren Ostergaard
    Lingvay, Ildiko
    Sondergaard, Anette Luther
    Treppendahl, Marianne Bach
    Montanya, Eduard
    DIABETES CARE, 2019, 42 (12) : 2272 - 2281
  • [48] Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
    Lai, Lee-Lee
    Vethakkan, Shireene Ratna
    Nik Mustapha, Nik Raihan
    Mahadeva, Sanjiv
    Chan, Wah-Kheong
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (02) : 623 - 631
  • [49] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
    Anderson, John E.
    Wright, Eugene E., Jr.
    Shaefer, Charles F., Jr.
    DIABETES THERAPY, 2017, 8 (01) : 33 - 53
  • [50] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
    John E. Anderson
    Eugene E. Wright
    Charles F. Shaefer
    Diabetes Therapy, 2017, 8 : 33 - 53
12345